You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Developing novel RPPA for the detection of metastatic prostate cancer
SBC: Tymora Analytical Operations, LLC Topic: 102PROJECT SUMMARY Reverse phase protein arrayRPPAhas emerged as a promising antibody based highly quantitative proteomic technology suitable for profiling proteins in hundreds to thousands of patient samplesThe throughputsensitivityand cost effectiveness of RPPAtogether with its ability to deal with minuscule sample amountshave propelled applications of the technology in basicpreclinical and clinica ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Target Identification for Novel Small Molecule Therapeutic for Alzheimer's disease
SBC: CoPlex Therapeutics, LLC Topic: NIAABSTRACT Traditional approaches to drug development for Alzheimer s disease are becoming increasingly expensive and in many cases disappointingly unsuccessful Based on preliminary in vitro and in vivo studies we have identified a novel small molecule methyl dimethyl oxo dihydrobenzo c naphthyridine carboxylate UK that significantly decreases A production and pro in ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Developing EV surface proteins as biosignatures for Alzheimer's disease (AD)
SBC: Tymora Analytical Operations, LLC Topic: NIAPROJECT SUMMARY The rising number of Americans currently living with Alzheimer’s disease (AD) demands pressing therapeutic and diagnostic solutions. The consensus is that early detection is critical to delay and better manage the disease. The recent discovery of extracellular vesicles (EVs) and their potentially important cellular functions in neuronal-glial communication, synaptic plasticity, o ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Developing high throughput measurement of thiopurine in DNA by mass spectrometry
SBC: Tymora Analytical Operations, LLC Topic: 400PROJECT SUMMARY Thiopurines such as mercaptopurine are S-substituted antimetabolites used as functional analogs to natural nucleobase precursors. They are highly effective against hematologic malignancies (leukemia and lymphoma) and autoimmune diseases (inflammatory bowel diseases [IBD]), with an estimated patient population andgt;350,000 in the US. However, the cytotoxicity of thiopurines depends ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Novel Nanosecond Laser and Ultrasound to Selectively Treat Eye Blood Vessels
SBC: Photosonox LLC Topic: NEIABSTRACT / PROJECT SUMMARY Wet age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. Anti-VEGF therapy is currently the gold standard for wet AMD treatment. However, up to 50% of patients in the long term have a suboptimal response to anti-VEGF therapy. A better alternative method for treatment of AMD is urgently needed. We have recently inve ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
An augmented reality platform to reduce post-operative and chronic opioid use in pediatric cancer
SBC: ALTALITY, INC. Topic: NIDAPROJECT SUMMARY/ABSTRACT Pediatric opioid use is a public health crisis. In children, prescription opioids are the primary source of non- medical abuse as well as opioid-associated hospitalizations and deaths. Early opioid use in childhood is a known “gateway” to adulthood dependence and substance abuse disorders. Despite years of research, opioids remain the most commonly prescribed pain medi ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Novel QcrB Inhibitors for the Treatment of Tuberculosis
SBC: LGENIA INC. Topic: NIAIDAbstract Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is the biggest killer among infectious diseases. TB is also responsible for a quarter of all deaths associated with Antimicrobial Resistance (AMR). It is projected that by 2050, 75 million people, or one person every 12 seconds, will die due to AMR associated with TB. Long treatment times and increasing resistance to TB drugs ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Stress forces huESC differentiation; confirmation as an accurate DevTox HTS
SBC: Reproductive Stress; Measurement, Mechanisms and Management, Corp. Topic: REXECUTIVE SUMMARY - huESC HTS2 - human Toxic stress effects in 1st trimester pregnancy leads to $10s of billions of US health care costs/year and is a significant part of the $2.5-4B/year US Developmental and Reproductive Technology (DART industry. Current DART techniques use slow, expensive pregnant rodent tests, or tests of embryonic stem cells (ESCs) that are cultured to lose “stemness” and ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Development of Hsp90 beta-selective inhibitors as safer anti-cancer agents
SBC: Grannus Therapeutics, Inc. Topic: NCIAbstract The 90 kD heat shock proteins (Hsp90) are molecular chaperones that are responsible for the folding of select proteins, many of which are directly associated with cancer progression. Consequently, inhibition of the Hsp90 protein folding machinery results in a combinatorial attack on numerous oncogenic pathways. Seventeen small molecule inhibitors of Hsp90 have entered clinical trials for ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Cerenkov Multi-Spectral Imaging (CMSI) for Adaptation and Real-Time Imaging in Radiotherapy
SBC: ENDECTRA, LLC Topic: 102PROJECT SUMMARY Understanding of tumor molecular characteristics during a course of radiotherapy (RT) treatment is crucial to assess the efficacy of the treatment and adapt radiation dosage to optimize outcomes. Unfortunately, this cannot be routinely achieved by current diagnostic nuclear imaging modalities due to complex logistics and prohibitive costs. Alternatively, Cerenkov Emission (CE) is a ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health